CION Ameerpet
SLL is a slow-growing B-cell lymphoma — and biologically the very same disease as chronic lymphocytic leukaemia (CLL). This guide explains the SLL vs CLL question clearly, how it is diagnosed and monitored, and how CION plans measured, evidence-led care.
Small lymphocytic lymphoma (SLL) is a slow-growing, or indolent, B-cell non-Hodgkin lymphoma. It is made up of small, mature-looking lymphocytes — a type of white blood cell — that build up and cause painless swelling, most often in the lymph nodes. It is one of the most common indolent lymphomas diagnosed in adults, and it typically develops over years rather than weeks.
The most important thing to understand about SLL is its close relationship with chronic lymphocytic leukaemia (CLL). SLL and CLL are not two different cancers — they are the same disease of mature B cells, simply presenting in different places. That single fact shapes how the disease is named, tested, monitored and treated, and it is why SLL care at CION is delivered hand-in-hand with our leukaemia programme.
This guide walks through the SLL vs CLL distinction, the symptoms, how the diagnosis is confirmed, the tests that predict behaviour, and how treatment is approached. For the full picture of lymphoma care, see our Lymphoma hub and our Lymphoma Treatment in Hyderabad page. SLL sits within the broader family of blood cancers.
The World Health Organization and international haematology bodies classify SLL and CLL as a single disease entity — "chronic lymphocytic leukaemia / small lymphocytic lymphoma". The only real difference is where the abnormal B cells collect: mainly in the lymph nodes (SLL) or mainly in the blood and bone marrow (CLL). Because they are one disease, the same staging, molecular tests and treatment principles apply to both. (Source: WHO classification of haematolymphoid tumours, as referenced in NCCN and ESMO CLL/SLL guidelines.)
If you have searched "sll vs cll", here is the simplest way to hold it in your head: it is one cancer of mature B cells, and the name just reflects where the cells are found.
| Feature | SLL (sll lymphoma) | CLL (leukaemia) |
|---|---|---|
| The cancer cell | Small, mature B lymphocyte | Small, mature B lymphocyte — identical |
| Where it collects | Mainly lymph nodes, spleen & marrow | Mainly circulating blood & bone marrow |
| How it shows up | Painless swollen glands | A raised lymphocyte count on a blood test |
| Surface markers | Both co-express CD5, CD23 and B-cell markers such as CD20 | |
| How it's managed | Same staging, same risk tests, same treatment principles | |
The distinction is defined on blood counts and biopsy findings, not by symptoms alone. Classification follows the WHO scheme and NCCN/ESMO guidance. Because CLL is the leukaemic form of the same disease, our leukaemia team is closely involved in SLL care.
Many people with SLL feel completely well and are found by chance. When symptoms do appear, they tend to be gradual.
The most common sign is one or more painless, slowly enlarging lymph nodes — in the neck, armpit or groin — often present for months before anyone worries.
Some people notice drenching night sweats, unexplained fevers, tiredness or weight loss. Frequent infections can occur because the immune system is affected.
Because SLL and CLL are one disease, our haematology and leukaemia specialists work together, so nothing falls between two silos. Every case is reviewed by a tumour board.
We treat only when treatment is genuinely needed, explain costs up front, and offer a free written second opinion. You can also compare our lymphoma hospital and specialist team.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Just been told you have SLL or CLL, want to understand what your reports mean, or need a second opinion before deciding whether to treat? CION's haematology team is here.
Confirming SLL — and telling it apart from other indolent lymphomas — follows a clear, step-by-step pathway. CION delivers biopsy coordination, laboratory testing, marrow examination and imaging within a single coordinated service.
Because SLL sits mainly in the nodes, an excisional biopsy — removing a whole affected lymph node — gives the pathologist the clearest picture, though a core needle biopsy may be done first. The tissue shows the characteristic pattern of small, mature B cells.
Flow cytometry reads the surface markers on the cells. SLL/CLL cells typically co-express CD5 and CD23 alongside B-cell markers such as CD20 — a fingerprint that separates SLL from lookalike lymphomas such as mantle cell lymphoma and marginal zone lymphoma.
A full blood count and a bone-marrow examination show how much disease is in the blood versus the nodes — this is what settles the SLL-versus-CLL label. A CT or PET-CT scan then maps how widely the nodes are involved for staging.
Finally, FISH for chromosome changes such as del(17p) and del(11q), TP53 mutation testing and IGHV mutation status help predict how the disease will behave and guide the timing and choice of treatment. NCCN and ESMO both recommend this assessment before any treatment decision. CION arranges these tests as standard.
SLL treatment is guided by whether the disease is causing problems, the stage, and your risk-test results. Every plan is set by a multidisciplinary tumour board before treatment begins. The building blocks are:
For many people with early, symptom-free SLL, the best evidence-based approach is not to treat straight away. Instead, the disease is monitored with regular reviews and blood tests, and treatment is started only if it progresses. This avoids the side effects of unnecessary therapy — an approach endorsed by NCCN and ESMO. Our guide to living with an indolent lymphoma explains how to live well during this phase.
When treatment is needed, the mainstays are described by class: an anti-CD20 monoclonal antibody and targeted oral therapy directed at B-cell signalling pathways. These are chosen partly on the FISH and TP53 results. CION delivers antibody and targeted therapy directly. For specific regimen names, see the treatment page.
In selected situations, chemotherapy or a short course of radiation therapy (IMRT) to a single bulky or troublesome node may be used. Both are delivered in-house by CION's medical and radiation oncology teams.
For higher-risk or relapsed disease, more intensive treatments such as stem-cell transplant or CAR-T cell therapy may be considered. These are coordinated through accredited partner centres rather than delivered in-house, and CION manages the referral and the surrounding care.
For indolent lymphomas like SLL, starting treatment straight away is often not the best choice. Large studies of early, symptom-free indolent lymphoma have found that immediate treatment does not improve how long people live compared with careful monitoring — which is why "watch-and-wait" is a recommended standard, not a delay tactic. Treatment is reserved for when the disease causes symptoms or progresses. (Source: NCCN and ESMO clinical practice guidelines for CLL/SLL and indolent B-cell lymphomas. Outcomes vary by individual.)
SLL is an indolent disease, and many people live with it for many years. The outlook depends heavily on the risk-test results — cases with a normal IGHV mutation pattern and no high-risk chromosome changes tend to stay quiet for a long time, while del(17p) or TP53-altered disease is watched more closely and treated with specific targeted classes.
It is worth putting lymphoma survival figures in context. Across lymphomas generally, published series report roughly 80–90% long-term survival for Hodgkin lymphoma and around 60–70% for diffuse large B-cell lymphoma (per published data referenced by NCCN and ESMO). Indolent lymphomas such as SLL are typically managed as a long-term condition rather than measured by a single cure figure. These numbers are general, published averages and vary considerably by individual — your own outlook depends on your stage, risk markers and health.
Uncommonly, an indolent SLL can transform into a faster-growing lymphoma, most often DLBCL — a pattern that echoes follicular lymphoma transformation. A node that suddenly grows fast, new fevers or rapid weight loss should prompt a review, since a repeat biopsy and a more intensive plan may be needed. This is exactly why ongoing monitoring matters even when SLL is behaving well. Speak to a CION haematologist if you notice any of these changes.
An SLL diagnosis carries real nuance, and a second opinion is especially valuable in a few situations:
CION offers a dedicated, free written second-opinion service. You deserve a plan built around your disease biology and your quality of life — with transparent costs explained up front. Request your free second opinion or call 18002028726.
Get a free written second opinion from CION's haematology tumour board — especially valuable if FISH, TP53 and IGHV testing has not yet been arranged on your SLL or CLL.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Small lymphocytic lymphoma is a slow-growing (indolent) B-cell non-Hodgkin lymphoma made up of small, mature-looking lymphocytes. It is one of the most common indolent lymphomas in adults and usually shows up as painless, enlarged lymph nodes. SLL is biologically the same disease as chronic lymphocytic leukaemia (CLL) — the difference is simply where the abnormal cells collect. When most of the disease sits in the lymph nodes it is called SLL; when large numbers of the same cells circulate in the blood and bone marrow it is called CLL. Both are handled by the same specialists using the same principles.
The "sll vs cll" question is one of the most common in this diagnosis, and the answer is reassuringly simple: SLL and CLL are two presentations of one and the same cancer of mature B lymphocytes. In CLL (chronic lymphocytic leukaemia), the abnormal cells are found mainly in the blood and bone marrow, so a blood count picks them up. In SLL (sll lymphoma), the same cells collect mainly in the lymph nodes, spleen and marrow, with few in the circulating blood — so it presents as swollen glands rather than an abnormal blood count. International bodies now classify them together as a single entity. Because they are one disease, the staging, testing and treatment approach overlap heavily, which is why SLL care is closely linked with our leukaemia programme.
SLL is an indolent (slow-growing) lymphoma. In most people it is not considered curable with standard therapy, but that is far less alarming than it sounds: it is often very manageable over many years, and many people live a long, full life with it. For details on watch-and-wait, when treatment starts and typical outcomes, see the Lymphoma Treatment in Hyderabad page. What matters most is accurate diagnosis, careful monitoring and a plan that treats only when treatment is needed. Learning to live well between reviews is a skill in itself — our guide on living with an indolent lymphoma covers this in depth.
Diagnosis rests on a tissue sample. Because SLL sits mainly in the nodes, an excisional lymph node biopsy (removing a whole node) gives the clearest answer, though a core needle biopsy may be used first. A pathologist confirms the small mature B-cell pattern, and flow cytometry checks the surface markers — SLL/CLL cells characteristically co-express CD5 and CD23 alongside B-cell markers such as CD20. A bone marrow examination and a blood count help judge how much disease is in the blood versus nodes (the SLL-versus-CLL distinction). A CT or PET-CT scan maps how widely nodes are involved. CION performs biopsy coordination, flow cytometry, marrow exam and imaging in a single coordinated pathway.
Beyond confirming the diagnosis, specific molecular and chromosome tests guide the outlook and timing of treatment. These include FISH testing for chromosome changes (such as del(17p) or del(11q)), TP53 mutation analysis, and the IGHV mutation status, which separates cases likely to stay quiet from those more likely to progress. These are testing concepts — knowing them helps the tumour board decide when to treat and which class of therapy fits best. NCCN and ESMO guidelines both recommend this risk assessment before starting treatment. We arrange these tests as standard on SLL tissue and blood, so your plan is built on your disease biology, not a one-size-fits-all rule.
Many people with early, symptom-free SLL need no immediate treatment — a monitored watch-and-wait approach with regular reviews is standard and evidence-based. Treatment begins when there are troublesome symptoms, rapidly enlarging nodes, or falling blood counts. When treatment is needed, options are described by class: anti-CD20 monoclonal antibody therapy, targeted oral therapy directed at B-cell signalling, and, in selected cases, chemotherapy or radiation to a bulky node. CION delivers chemotherapy, antibody and targeted therapy, radiation, biopsy and monitoring directly; more intensive options such as stem-cell transplant or CAR-T cell therapy are coordinated through accredited partner centres when appropriate. Every plan is set by a multidisciplinary tumour board. For regimen-level detail, see our treatment page.
Occasionally, an indolent SLL can change into a more aggressive lymphoma — most often a diffuse large B-cell lymphoma (DLBCL). This is uncommon, but it is why ongoing monitoring matters even when the disease is quiet. Warning signs include a lymph node that suddenly grows quickly, new drenching night sweats, unexplained fevers or rapid weight loss. If transformation is suspected, a repeat biopsy of the changing node confirms it, and treatment then shifts to a more intensive, aggressive-lymphoma approach. Because the pattern mirrors what can happen in follicular lymphoma transformation, our team watches for it closely and acts promptly if it occurs.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.